Limits...
Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy.

Kleef R, Kekic S, Ludwig N - Case Rep Oncol (2012)

Bottom Line: Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells.No other treatment was given to the patient.Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.

View Article: PubMed Central - PubMed

Affiliation: Dr. Kleef - Hyperthermie, Stiftung Integrative Onkologie, Vienna, Austria.

ABSTRACT
We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m(2)/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range long-duration whole-body hyperthermia (WBH) was performed at the temperature plateau of 40°C body core temperature for 6 h. Three months after completion of chemotherapy, 4 more long-duration WBH procedures were performed in monthly intervals. Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells. No other treatment was given to the patient. Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.

No MeSH data available.


Related in: MedlinePlus

Development of tumor marker CA125. CHT = Chemotherapy; LD-WBH = long-duration WBH.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3369243&req=5

Figure 1: Development of tumor marker CA125. CHT = Chemotherapy; LD-WBH = long-duration WBH.

Mentions: Restaging by full laboratory analysis including TM CA125, CEA and CT of the abdomen was performed in 6-month intervals. The patient is now, 4 years following the initial diagnosis, free of any signs of cancer in lasting complete remission. The CT of the abdomen in May and October 2008 and June and December 2009 all showed no signs of cancer recurrence. The TM CA125, which could be taken as laboratory surrogate marker, was still in the normal range in November 2011. An analysis of circulating tumor cells from the blood (PCR detection of tumor-specific gene expression) in December 2009 was negative (fig. 1).


Successful treatment of advanced ovarian cancer with thermochemotherapy and adjuvant immune therapy.

Kleef R, Kekic S, Ludwig N - Case Rep Oncol (2012)

Development of tumor marker CA125. CHT = Chemotherapy; LD-WBH = long-duration WBH.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3369243&req=5

Figure 1: Development of tumor marker CA125. CHT = Chemotherapy; LD-WBH = long-duration WBH.
Mentions: Restaging by full laboratory analysis including TM CA125, CEA and CT of the abdomen was performed in 6-month intervals. The patient is now, 4 years following the initial diagnosis, free of any signs of cancer in lasting complete remission. The CT of the abdomen in May and October 2008 and June and December 2009 all showed no signs of cancer recurrence. The TM CA125, which could be taken as laboratory surrogate marker, was still in the normal range in November 2011. An analysis of circulating tumor cells from the blood (PCR detection of tumor-specific gene expression) in December 2009 was negative (fig. 1).

Bottom Line: Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells.No other treatment was given to the patient.Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.

View Article: PubMed Central - PubMed

Affiliation: Dr. Kleef - Hyperthermie, Stiftung Integrative Onkologie, Vienna, Austria.

ABSTRACT
We report on a 4-year progression-free survival of a 54-year-old female first diagnosed in December 2007 with advanced bilateral ovarian cancer FIGO IIIc, disseminated peritoneal carcinosis and malignant diaphragm invasion. Treatment started in January 2008 with 6 cycles of Taxol 175 mg/m(2)/carboplatin AUC 5 in 3-week intervals. Twenty-four hours following each chemotherapy session, fever-range long-duration whole-body hyperthermia (WBH) was performed at the temperature plateau of 40°C body core temperature for 6 h. Three months after completion of chemotherapy, 4 more long-duration WBH procedures were performed in monthly intervals. Importantly, long-duration WBH was paralleled with intradermal vaccination of autologous dendritic cells. No other treatment was given to the patient. Four years following the first diagnosis, the patient is still in complete remission with no evidence of disease.

No MeSH data available.


Related in: MedlinePlus